Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

High-Dose Cyclophosphamide for Steroid Refractory GVHD

Phase 2

Completed

Conditions: Graft Versus Host Disease

Interventions: Drug: Cyclophosphamide

First Posted Date: 2007-06-27

Last Posted Date: 2018-09-14

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 12

Registration Number: NCT00492921

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL

Phase 2

Completed

Conditions: Lymphoma, Mantle-Cell

Interventions: Biological: CpG-MCL vaccine
Biological: PF-3512676
Procedure: Vaccine-primed T-cells
Procedure: Autologous hematopoietic stem cell transplant (HSCT)
Drug: Rituximab
Drug: Standard induction chemotherapy
Drug: Cyclophosphamide
Drug: Filgrastim

First Posted Date: 2007-06-22

Last Posted Date: 2020-01-13

Lead Sponsor: Ronald Levy

Target Recruit Count: 59

Registration Number: NCT00490529

Locations: 🇺🇸
Stanford University Medical Center, Stanford, California, United States

Non-Myeloablative Bone Marrow Transplant for Patients With Sickle Cell Anemia and Other Blood Disorders

Phase 2

Terminated

Conditions: Sickle Cell Disease

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Mycophenolate mofetil
Drug: Sirolimus
Procedure: Allogeneic bone marrow transplant
Radiation: Total body irradiation - 200
Drug: Levetiracetam
Biological: Anti-thymocyte globulin
Radiation: Total body irradiation - 400

First Posted Date: 2007-06-21

Last Posted Date: 2019-04-17

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 43

Registration Number: NCT00489281

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer

Phase 3

Conditions: Invasive Breast Cancer

Interventions: Drug: doxorubicin
Drug: cyclophosphamide
Drug: paclitaxel
Drug: trastuzumab
Drug: lapatinib

First Posted Date: 2007-06-15

Last Posted Date: 2016-06-06

Lead Sponsor: NSABP Foundation Inc

Target Recruit Count: 529

Registration Number: NCT00486668

Locations: 🇺🇸
CCOP, William Beaumont Hospital, Royal Oak, Michigan, United States
🇺🇸
CCOP, Hematology-Oncology Associates of CNY, Syracuse, New York, United States
🇺🇸
Lehigh Valley Hospital, Allentown, Pennsylvania, United States

and more 107 locations

Randomized Trial of IVIg With or Without Cyclophosphamide in Pemphigus

Phase 2

Terminated

Conditions: Pemphigus Vulgaris

Interventions: Drug: intravenous immunoglobulin
Drug: cyclophosphamide

First Posted Date: 2007-06-06

Last Posted Date: 2016-02-18

Lead Sponsor: NYU Langone Health

Target Recruit Count: 9

Registration Number: NCT00483119

Locations: 🇺🇸
NYU Medical Center, New York, New York, United States

Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma

Phase 2

Terminated

Conditions: Malignant Conjunctival Neoplasm
Intraocular Melanoma

Interventions: Drug: cyclophosphamide
Drug: sunitinib malate
Drug: lenalidomide

First Posted Date: 2007-06-05

Last Posted Date: 2017-03-27

Lead Sponsor: National Institutes of Health Clinical Center (CC)

Target Recruit Count: 12

Registration Number: NCT00482911

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States

Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Biological: trastuzumab
Drug: cyclophosphamide
Drug: doxorubicin hydrochloride
Drug: lapatinib ditosylate
Drug: paclitaxel
Other: laboratory biomarker analysis

First Posted Date: 2007-06-05

Last Posted Date: 2017-05-12

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 95

Registration Number: NCT00482391

Locations: 🇺🇸
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT

Phase 2

Terminated

Conditions: Lymphoma, B-cell
Lymphoma, Non-Hodgkin
Diffuse Large B-cell Lymphoma (DLBCL)
Malignant Lymphoma, Non-Hodgkin

Interventions: Procedure: Autologous hematopoietic stem cell transplantation (auto-HSCT)
Procedure: Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
Procedure: Total lymphoid irradiation (TLI)
Drug: Rituximab
Drug: Carmustine
Drug: Etoposide
Drug: Filgrastim
Drug: Anti-thymocyte globulin (ATG)
Drug: Cyclosporine
Drug: Mycophenolate mofetil (MMF)
Drug: Cyclophosphamide
Drug: Acetaminophen
Drug: Diphenhydramine
Drug: Hydrocortisone
Drug: Methylprednisolone

First Posted Date: 2007-06-04

Last Posted Date: 2018-05-14

Lead Sponsor: Stanford University

Target Recruit Count: 3

Registration Number: NCT00482053

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma

Phase 2

Terminated

Conditions: Lymphoma, Non-Hodgkin

Interventions: Drug: Cyclophosphamide
Drug: BCNU
Drug: Etoposide
Drug: Filgrastim
Drug: Antithymocyte globulin
Drug: Cyclosporine
Drug: Mycophenolate mofetil
Drug: Rituximab
Procedure: Autologous hematopoietic stem cell transplantation (auto-HSCT)
Procedure: Allogeneic hematopoietic stem cell transplantation (allo-HSCT)
Procedure: Total lymphoid irradiation
Drug: CD34+ Cells
Drug: Solu-Medrol